<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37822090</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2141</ISSN><JournalIssue CitedMedium="Internet"><Volume>204</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Month>Feb</Month></PubDate></JournalIssue><Title>British journal of haematology</Title><ISOAbbreviation>Br J Haematol</ISOAbbreviation></Journal><ArticleTitle>Prolonged platelet hyperactivity after COVID-19 infection.</ArticleTitle><Pagination><StartPage>492</StartPage><EndPage>496</EndPage><MedlinePgn>492-496</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bjh.19125</ELocationID><Abstract><AbstractText>Platelet hyperactivity often occurs in patients with coronavirus disease 2019 (COVID-19). However, it remains unclear how long platelet hyperactivity lasts after the acute phase, owing to a lack of follow-up studies. To elucidate the course of platelet hyperactivity, we serially measured platelet activity in patients with COVID-19 up to 40&#x2009;days after hospital admission using an easily assessable haematology analyser that semi-quantitates platelet clumps on a scattergram. Our results showed that platelet hyperactivity persisted for at least 40&#x2009;days even after acute inflammation subsided in most patients with COVID-19, regardless of disease severity. Persistent platelet hyperactivity may contribute to thromboembolic complications in post-COVID-19 patients.</AbstractText><CopyrightInformation>&#xa9; 2023 British Society for Haematology and John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nara</LastName><ForeName>Noriko</ForeName><Initials>N</Initials><Identifier Source="ORCID">0009-0004-5543-3345</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Yokohama Brain and Spine Center, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimizu</LastName><ForeName>Mie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Yokohama Brain and Spine Center, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Masahiro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Yokohama Brain and Spine Center, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamizo</LastName><ForeName>Tomoki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Clinical Studies, Radiation Effects Research Foundation, Nagasaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hayakawa</LastName><ForeName>Azusa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Yokohama Brain and Spine Center, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johkura</LastName><ForeName>Ken</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Yokohama Brain and Spine Center, Yokohama, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Yokohama Foundation for the Advancement of Medical Science</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Haematol</MedlineTA><NlmUniqueID>0372544</NlmUniqueID><ISSNLinking>0007-1048</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Br J Haematol. 2024 Feb;204(2):383-385. doi: 10.1111/bjh.19159</RefSource><PMID Version="1">37872820</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001792" MajorTopicYN="N">Blood Platelets</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">haematology analyser</Keyword><Keyword MajorTopicYN="N">long COVID-19</Keyword><Keyword MajorTopicYN="N">platelet clumps</Keyword><Keyword MajorTopicYN="N">platelet hyperactivity</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>12</Day><Hour>2</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37822090</ArticleId><ArticleId IdType="doi">10.1111/bjh.19125</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28(3):583-590.</Citation></Reference><Reference><Citation>Xu E, Xie Y, Al-Aly Z. Long-term neurologic outcomes of COVID-19. Nat Med. 2022;28(11):2406-2415.</Citation></Reference><Reference><Citation>Manne BK, Denorme F, Middleton EA, Portier I, Rowley JW, Stubben C, et al. Platelet gene expression and function in patients with COVID-19. Blood. 2020;136(11):1317-1329.</Citation></Reference><Reference><Citation>Hottz ED, Azevedo-Quintanilha IG, Palhinha L, Teixeira L, Barreto EA, P&#xe3;o CRR, et al. Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19. Blood. 2020;136(11):1330-1341.</Citation></Reference><Reference><Citation>Nishikawa M, Kanno H, Zhou Y, Xiao TH, Suzuki T, Ibayashi Y, et al. Massive image-based single-cell profiling reveals high levels of circulating platelet aggregates in patients with COVID-19. Nat Commun. 2021;12(1):7135.</Citation></Reference><Reference><Citation>Sugawara E, Shimizu M, Yamamoto M, Kudo Y, Tanaka F, Johkura K. Pitfall of light transmission aggregometry-based assessment of platelet function in acute ischemic stroke patients. J Stroke Cerebrovasc Dis. 2020;29(1):104496.</Citation></Reference><Reference><Citation>Sugawara E, Shimizu M, Yamamoto M, Kudo Y, Tanaka F, Johkura K. Influence of platelet aggregate formation in blood samples on light transmission aggregometry results. J Stroke Cerebrovasc Dis. 2019;28(4):1001-1006.</Citation></Reference><Reference><Citation>Shimizu M, Yamamoto M, Miyachi H, Shinohara Y, Ando Y. Simple, rapid, and automated method for detection of hyperaggregability of platelets using a hematology analyzer. Am J Hematol. 2003;72(4):282-283.</Citation></Reference><Reference><Citation>Shimizu M, Kamio K, Iwamoto T, Ando Y, Kuwahira I. Simple, rapid and automated method for detection of hyperaggregability of platelets in sleep apnea syndrome. J Thromb Haemost. 2006;4(4):920-922.</Citation></Reference><Reference><Citation>Scott CS, Van Zyl D, Ho E, Ruivo L, Mendelow B, Coetzer TL. Thrombocytopenia in patients with malaria: automated analysis of optical platelet counts and platelet clumps with the cell Dyn CD4000 analyser. Clin Lab Haematol. 2002;24(5):295-302.</Citation></Reference><Reference><Citation>Ishikawa T, Shimizu M, Kohara S, Takizawa S, Kitagawa Y, Takagi S. Appearance of WBC-platelet complex in acute ischemic stroke, predominantly in atherothrombotic infarction. J Atheroscler Thromb. 2012;19(5):494-501.</Citation></Reference><Reference><Citation>Lisman T. Platelet-neutrophil interactions as drivers of inflammatory and thrombotic disease. Cell Tissue Res. 2018;371(3):567-576.</Citation></Reference><Reference><Citation>Tajarernmuang P, Phrommintikul A, Limsukon A, Pothirat C, Chittawatanarat K. The role of mean platelet volume as a predictor of mortality in critically ill patients: a systematic review and meta-analysis. Crit Care Res Pract. 2016;2016:4370834.</Citation></Reference><Reference><Citation>Gu SX, Tyagi T, Jain K, Gu VW, Lee SH, Hwa JM, et al. Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation. Nat Rev Cardiol. 2021;18(3):194-209.</Citation></Reference><Reference><Citation>Fogarty H, Townsend L, Morrin H, Ahmad A, Comerford C, Karampini E, et al. Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J Thromb Haemost. 2021;19(10):2546-2553.</Citation></Reference><Reference><Citation>von Meijenfeldt FA, Havervall S, Adelmeijer J, Thalin C, Lisman T. Persistent endotheliopathy in the pathogenesis of long COVID syndrome: comment from von Meijenfeldt et al. J Thromb Haemost. 2022;20(1):267-269.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>